Kiora Pharmaceuticals (KPRX) Short term Debt (2016 - 2023)
Kiora Pharmaceuticals' (KPRX) quarterly Short term Debt came in at $495000.0 in Q3 2023, up 57.79% YoY from $313714.0 in Q3 2022, and up 57.72% on a QoQ basis from $313853.0 in Q2 2023.
Kiora Pharmaceuticals (KPRX) Short term Debt (2016 - 2023) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 3 years of Short term Debt data on file, last reported at $495000.0 in Q3 2023.
- Quarterly Short term Debt rose 57.79% year-over-year to $495000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $495000.0 (up 57.79% YoY) and the FY2022 annual result came in at $322385.0, changed N/A from the prior year.
- Short term Debt advanced to $495000.0 in Q3 2023, from $313853.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $495000.0 in Q3 2023 to a low of $293947.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 495,000.00 |
| Jun 30, 2023 | 313,853.00 |
| Mar 31, 2023 | 313,299.00 |
| Dec 31, 2022 | 322,385.00 |
| Sep 30, 2022 | 313,714.00 |
| Jun 30, 2022 | 301,808.00 |
| Mar 31, 2022 | 293,947.00 |
| Mar 31, 2016 | 1.21 Mn |